Trevi Therapeutics
New Haven
Connecticut
United States
Tel: 203-304-2499
Fax: 203-304-2434
Website: http://www.trevitherapeutics.com/
Email: info@trevitherapeutics.com
80 articles with Trevi Therapeutics
-
Trevi Therapeutics to Present at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases
11/15/2021
Trevi Therapeutics, Inc. today announced that Dr. Bill Forbes , Chief Development Officer, will be presenting at the 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases taking place from November 16-18, 2021 in Boston, MA.
-
Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update
11/10/2021
Trevi Therapeutics, Inc. today announced financial results for the quarter ended September 30, 2021, as well as provided business updates.
-
Trevi Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference
11/9/2021
Trevi Therapeutics, Inc. today announced that senior leadership members will participate in a virtual fireside chat, as well as host investor meetings, at the Stifel 2021 Virtual Healthcare Conference on November 15, 2021.
-
Trevi Therapeutics to Report Q3 2021 Financial Results and Provide a Corporate Update on Wednesday, November 10, 2021
11/3/2021
Trevi Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on Wednesday, November 10 at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the third quarter ended September 30, 2021.
-
Trevi Therapeutics to Present at 11th World Congress on Itch (WCI)
10/13/2021
Trevi Therapeutics, Inc. today announced that Dr. Bill Forbes , Chief Development Officer, will present as part of a virtual viewpoint session at the 11th World Congress on Itch (WCI) taking place from October 22-23, 2021.
-
Trevi Therapeutics Participating in Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference
10/7/2021
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that senior management will be available for virtual one-on-one meetings at Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference.
-
Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market
10/1/2021
Trevi Therapeutics, Inc. announced that it has entered into a definitive agreement with a healthcare-focused institutional investor, for the purchase, in a private placement priced at-the-market under Nasdaq rules, of 2,373,201 shares of common stock and accompanying warrants to purchase an aggregate of 4,746,402 shares of common stock.
-
BioSpace Movers & Shakers, Aug. 13
8/13/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Trevi Therapeutics Announces Second Quarter 2021 Financial Results and Business Update
8/12/2021
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ to treat serious neurologically mediated conditions, announced financial results for the quarter ended June 30, 2021, as well as business updates.
-
Trevi Therapeutics Announces Additions to the Senior Leadership Team
8/9/2021
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ to treat serious neurologically mediated conditions, announced the appointment of Lisa Delfini, CPA, as Chief Financial Officer and Danine Summers, as Vice President, Medical Affairs.
-
Trevi Therapeutics to Report Q2 2021 Financial Results on August 12
8/5/2021
Trevi Therapeutics, Inc. (Nasdaq: TRVI), today announced that management will host a conference call and live audio webcast on Thursday, August 12 at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended June 30, 2021.
-
Trevi Therapeutics to Present at 2021 BIO Digital Conference
6/9/2021
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that Jennifer Good, President and CEO, has b
-
Trevi Therapeutics Announces First Quarter 2021 Financial Results and Business Update
5/13/2021
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended March 31, 2021, as well as business updates
-
Trevi Therapeutics to Report Q1 2021 Financial Results on May 13
5/6/2021
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ to treat serious neurologically mediated conditions, announced that management will host a conference call and live audio webcast on Thursday, May 13 at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31, 2021.
-
Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
4/7/2021
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will participate in a virtual fireside chat, as well as host investor meetings, at the 20 th Annual Needham Virtual Healthcare Conference on April 14, 2021.
-
Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates
3/25/2021
Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021 Cash Position Expected to Fund Operations into the Second Quarter of 2022
-
Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25Conference Call and Webcast to be Held at 4:30 p.m. ET
3/18/2021
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on March 25, 2021
-
Trevi Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference
2/18/2021
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will participate in a virtual fireside chat, as well as host virtual investor meetings, at the 10 th Annual SVB Leerink Global Healthcare Conference on February 25, 2021.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Trevi Therapeutics Appoints William Forbes, Pharm.D. as Chief Development Officer
2/1/2021
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced the appointment of William Forbes, Pharm.D., as Chief Development Officer.